Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03955783
Title Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Michael Byrne

diffuse large B-cell lymphoma

acute myeloid leukemia


Selinexor + Venetoclax

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.